Most　anticancer　treatments　only　induce　the　death　of　ordinary　cancer　cells,　while　cancer　stem　cells　(CSCs)　in　the　quiescent　phase　of　cell　division　are　difficult　to　kill,　which　eventually　leads　to　cancer　drug　resistance,　metastasis,　and　relapse.　Therefore,　CSCs　are　also　important　in　targeted　cancer　therapy.　Herein,　we　developed　dual-targeted　and　glutathione　(GSH)-responsive　novel　nanoparticles　(SSBPEI-DOX@siRNAs/iRGD-PEG-HA)　to　efficiently　and　specifically　deliver　both　doxorubicin　and　small　interfering　RNA　cocktails　(siRNAs)　(survivin　siRNA,　Bcl-2　siRNA　and　ABCG2　siRNA)　to　ovarian　CSCs.　They　are　fabricated　via　electrostatic　assembly　of　anionic　siRNAs　and　cationic　disulfide　bond　crosslinking-branched　polyethyleneimine-doxorubicin　(SSBPEI-DOX)　as　a　core.　Interestingly,　the　SSBPEI-DOX　could　be　degraded　into　low-cytotoxic　polyethyleneimine　(PEI).　Because　of　the　enrichment　of　glutathione　reductase　in　the　tumor　microenvironment,　the　disulfide　bond　(-SS-)　in　SSBPEI-DOX　can　be　specifically　reduced　to　promote　the　controlled　release　of　siRNA　and　doxorubicin　(DOX)　in　the　CSCs.　siRNA　cocktails　could　specifically　silence　three　key　genes　in　CSCs,　which,　in　combination　with　the　traditional　chemotherapy　drug　DOX,　induces　apoptosis　or　necrosis　of　CSCs.　iRGD　peptides　and　＂sheddable＂　hyaluronic　acid　(HA)　wrapped　around　the　core　could　mediate　CSC　targeting　by　binding　with　neuropilin-1　(NRP1)　and　CD44　to　enhance　delivery.　In　summary,　the　multifunctional　delivery　system　SSBPEI-DOX@siRNAs/iRGD-PEG-HA　nanoparticles　displays　excellent　biocompatibility,　accurate　CSC-targeting　ability,　and　powerful　anti-CSC　ability,　which　demonstrates　its　potential　value　in　future　treatments　to　overcome　ovarian　cancer　metastasis　and　relapse.　To　support　this　work,　as　exhaustive　search　was　conducted　for　the　literature　on　nanoparticle　drug　delivery　research　conducted　in　the　last　17　years　(2007-2023)　using　PubMed,　Web　of　Science,　and　Google　Scholar.